SMSF trustees should review suspended or delisted holdings before 30 June 2026. Realising these positions will crystallise capital losses (usable against future gains) and simplify fund portfolios ahead of the Division 296 reset.
SMSF trustees should review suspended or delisted holdings before 30 June 2026. Realising these positions will crystallise capital losses (usable against future gains) and simplify fund portfolios ahead of the Division 296 reset.
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
15 May 2026
| Name: | PROGEN PHARMACEUTICALS LIMITED (PGL) (This company subsequently changed its name and is now TBG DIAGNOSTICS LIMITED. You should refer to that name for Status.) | ||||||
| Date of Listing: | 22 December 1995 | ||||||
| Subsequent Names: |
| ||||||
| Former Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now TBG DIAGNOSTICS LIMITED. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now TBG DIAGNOSTICS LIMITED. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now TBG DIAGNOSTICS LIMITED. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| TBG DIAGNOSTICS LIMITED | 02/02/2016 | |
| PROGEN PHARMACEUTICALS LIMITED | 02/04/2007 | 02/02/2016 |
| PROGEN INDUSTRIES LIMITED | 02/04/2007 |
REGISTRY:
Computershare Brisbane
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail
name changed to TBG Diagnostics Limited | 02/02/2016 |
The company provides the following update: the company is working towards a relisting date of 3 February, 2016; the company has completed the acquisition of TBG Inc.; it has received valid applications for a total of 60,579,000 new shares which represents a total raising of $12,721,590 which were issued to investors pursuant to the terms of the offer under the prospectus; company will change its ASX code; and it has also provided an indicative timetable. | 29/01/2016 |
TBG Diagnostics Limited (formerly Progen Pharmaceuticals Ltd) advises that the following unlisted options issued under the Company's Employee Share Option Plan have lapsed: Number: 90,000 Exercise Price: $0.29 Expiry: 1 January 2016 | 29/01/2016 |
The company is pleased to announce that the Company has received valid applications for a total of 69,579,000 new shares under the Prospectus dated 10 November 2015, which represents a total raising of $12,721,590. | 11/12/2015 |
The securities of Progen Pharmaceuticals Limited (the "Company") will be suspended from quotation immediately, following receipt of security holder approval concerning a transaction which will result in a significant change to the Company's scale. The Company's securities will remain suspended until the Company has complied with Chapters 1 and 2 of the Listing Rules in accordance with Listing Rule 11.1.3. Security Code: PGL | 07/12/2015 |
name changed from Progen Industries Limited | 02/04/2007 |
name changed to TBG Diagnostics Limited | 02/02/2016 |
The company provides the following update: the company is working towards a relisting date of 3 February, 2016; the company has completed the acquisition of TBG Inc.; it has received valid applications for a total of 60,579,000 new shares which represents a total raising of $12,721,590 which were issued to investors pursuant to the terms of the offer under the prospectus; company will change its ASX code; and it has also provided an indicative timetable. | 29/01/2016 |
TBG Diagnostics Limited (formerly Progen Pharmaceuticals Ltd) advises that the following unlisted options issued under the Company's Employee Share Option Plan have lapsed: Number: 90,000 Exercise Price: $0.29 Expiry: 1 January 2016 | 29/01/2016 |
The company is pleased to announce that the Company has received valid applications for a total of 69,579,000 new shares under the Prospectus dated 10 November 2015, which represents a total raising of $12,721,590. | 11/12/2015 |
The securities of Progen Pharmaceuticals Limited (the "Company") will be suspended from quotation immediately, following receipt of security holder approval concerning a transaction which will result in a significant change to the Company's scale. The Company's securities will remain suspended until the Company has complied with Chapters 1 and 2 of the Listing Rules in accordance with Listing Rule 11.1.3. Security Code: PGL | 07/12/2015 |
name changed from Progen Industries Limited | 02/04/2007 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 14/05/2014 | Jitto Arulampalam | On market | 40,000 | $1.010 | $40,398 |
| 12/03/2014 | Heng Tang | On market | 10,000 | $0.520 | $5,200 |
| 12/12/2013 | Heng Tang | On market | 10,000 | $0.220 | $2,196 |
| 06/12/2013 | Heng Tang | On market | 33,000 | $0.227 | $7,475 |
| 26/03/2013 | Woei-Jia Jiang | On market | 13,389 | $0.230 | $3,079 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Jitto Arulampalam | Non Exec Chairman | 12/06/2013 |
| Emily Lee | Director | 07/12/2015 |
| Eugene Cheng | Director | 07/12/2015 |
| Stanley Chang | Director | 07/12/2015 |
| Blair Lucas | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Christopher Harvey | Independent Director | 16/03/2015 | 07/12/2015 |
| Hongjen Chang | Non Exec Director | 29/11/2013 | 07/12/2015 |
| Heng Tang | Managing Director, CEO | 17/07/2009 | 16/03/2015 |
| Stuart James | Non Exec Chairman | 01/07/2009 | 28/11/2013 |
| Woei-Jia Jiang | Director | 16/06/2011 | 12/07/2013 |
| Paul Dixon | CFO | 03/04/2009 | 12/10/2012 |
| Thomas Burt | Non Exec Director | 17/07/2009 | 30/11/2011 |
| Sue MacLeman | CEO | 06/04/2010 | 26/08/2011 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2026 Investogain Pty Limited. All rights reserved.
